Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid (2016)
- Authors:
- USP affiliated authors: GATTAZ, WAGNER FARID - FM ; FORLENZA, ORESTES VICENTE - FM
- Unidade: FM
- DOI: 10.1111/bdi.12360
- Subjects: BIOMARCADORES; TRANSTORNO BIPOLAR; LÍQUIDO CEFALORRAQUIDIANO; DOENÇA DE ALZHEIMER
- Language: Inglês
- Imprenta:
- Publisher place: Copenhagen
- Date published: 2016
- Source:
- Título: Bipolar Disorders
- ISSN: 1398-5647
- Volume/Número/Paginação/Ano: v. 18, n. 1, p. 63-70, 2016
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
FORLENZA, Orestes V. et al. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Bipolar Disorders, v. 18, n. 1, p. 63-70, 2016Tradução . . Disponível em: http://onlinelibrary.wiley.com/doi/10.1111/bdi.12360/epdf. Acesso em: 10 jan. 2026. -
APA
Forlenza, O. V., Aprahamian, I., Radanovic, M., Talib, L. L., Camargo, M. von Z. de A., Stella, F., et al. (2016). Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Bipolar Disorders, 18( 1), 63-70. doi:10.1111/bdi.12360 -
NLM
Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo M von Z de A, Stella F, Machado-Vieira R, Gattaz WF. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid [Internet]. Bipolar Disorders. 2016 ; 18( 1): 63-70.[citado 2026 jan. 10 ] Available from: http://onlinelibrary.wiley.com/doi/10.1111/bdi.12360/epdf -
Vancouver
Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo M von Z de A, Stella F, Machado-Vieira R, Gattaz WF. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid [Internet]. Bipolar Disorders. 2016 ; 18( 1): 63-70.[citado 2026 jan. 10 ] Available from: http://onlinelibrary.wiley.com/doi/10.1111/bdi.12360/epdf - Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial
- Single-nucleotide polymorphisms of GSK3B, GAB2 and SORL1 in late-onset Alzheimer's disease: interactions with the APOE genotype
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Lithium efficacy in bipolar depression with flexible dosing: A six-week, open-label, proof-of-concept study
- Inhibition of phospolipase A2 modulates glycogen synthase activity and tau phosphorylation in primary cultures of cortical and hippocampal neurons
- Low platelet iPLA2 activity predicts conversion from mild cognitive impairment to Alzheimer’s disease: a 4-year follow-up study
- Interleukin-1β Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients
- Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease
- Diagnosis and biomarkers of predementia in Alzheimer’s disease
Informações sobre o DOI: 10.1111/bdi.12360 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
